Insights

Gathering insights about VBP…

Similar companies to VBP

VBP Tech Stack

VBP uses 8 technology products and services including QuickBooks, WordPress, Zoho, and more. Explore VBP's tech stack below.

QuickBooks
Accounting And Finance
WordPress
Content Management System
Zoho
Customer Relationship Management
PostgreSQL
Database
oEmbed
Dev Tools
Azure DevOps
Devops
ISO/IEC 27001
Governance, Risk And Compliance
imagesLoaded
Javascript Libraries

Media & News

Leon Cooperman's Strategic Moves: Mr. Cooper Group Inc. Exits with -18.82% Impact
Insight into Leon Cooperman (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing Leon Cooperman (Trades, Portfolio) recently submitted the 13F filing for the f
Feb 17, 2026 | www.gurufocus.com
$207B Market Shift: The Race for Fast Track Approval in Oncology
/PRNewswire/ -- USANewsGroup.com News Commentary - The FDA isn't just approving drugs; they are completely reshaping the landscape. In 2025 alone, the agency
Feb 05, 2026 | www.prnewswire.com
ArriVent BioPharma: Its Leading Asset Furmonertinib Supports A Cautious Buy
ArriVent BioPharma (AVBP) is a cautious BUY, driven by furmonertinib's late-stage potential in uncommon EGFR-mutant NSCLC and a conservative valuation approach. AVBP's strategy targets niche EGFR mutations—exon 20 insertions, PACC, and others—where competition is less entrenched and regulatory pathways are more navigable. Furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials, supporting risk-adjusted U.S. revenue estimates of $600M–$900M annually.
Jan 04, 2026 | seekingalpha.com
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts
ArriVent BioPharma is rated a Strong Buy, driven by Firmonertinib's near-term clinical catalysts and significant de-risking from Shanghai Allist Pharmaceuticals commercialization. Firmonertinib has continued to deliver encouraging efficacy with a tolerable safety profile across treated patients. Under conservative assumptions, there is an asymmetric valuation setup.
Dec 25, 2025 | seekingalpha.com
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
NEWTOWN SQUARE, Pa., Dec. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the first patient has been dosed in the global pivotal Phase 3 ALPACCA study evaluating firmonertinib monotherapy for first-line treatment of EGFR PACC mutant non-small cell lung cancer (NSCLC). Firmonertinib is an oral, once daily, highly brain-penetrant and broadly active mutation-selective EGFR inhibitor.
Dec 22, 2025 | www.globenewswire.com
12,735 Shares in ArriVent BioPharma, Inc. $AVBP Acquired by AXQ Capital LP
AXQ Capital LP acquired a new stake in ArriVent BioPharma, Inc. (NASDAQ: AVBP) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 12,735 shares of the company's stock, valued at approximately $277,000. A number of other institutional investors have also recently
Nov 25, 2025 | www.defenseworld.net
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of “Moderate Buy” from Analysts
ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) has earned an average rating of "Moderate Buy" from the nine ratings firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating on
Nov 25, 2025 | www.defenseworld.net

VBP's Email Address Formats

VBP uses at least 2 format(s):

VBP Email Formats	Example	Percentage
First.Last@virtualbusinesspartners.com.au	John.Doe@virtualbusinesspartners.com.au	94%
First@virtualbusinesspartners.com.au	John@virtualbusinesspartners.com.au	6%
First.Last@vbp.au	John.Doe@vbp.au	100%

Frequently Asked Questions

Where is VBP's headquarters located?

VBP's main headquarters is located at 88 Philip Street Level Sydney, New South Wales 2000 Australia. The company has employees across 6 continents, including AsiaOceaniaNorth America.

What is VBP's stock symbol?

VBP is a publicly traded company; the company's stock symbol is AVBP.

What is VBP's official website and social media links?

VBP's official website is vbp.au and has social profiles on LinkedIn.

What is VBP's NAICS code?

VBP's NAICS code is 52 - Finance and Insurance.

How many employees does VBP have currently?

As of February 2026, VBP has approximately 1.1K employees across 6 continents, including AsiaOceaniaNorth America. Key team members include Chief Executive Officer: N. J.Chief Executive Officer: L. F.Chief Information And Digital Officer: S. N.. Explore VBP's employee directory with LeadIQ.

What industry does VBP belong to?

VBP operates in the Financial Services industry.

What technology does VBP use?

VBP's tech stack includes QuickBooksWordPressZohoPostgreSQLoEmbedAzure DevOpsISO/IEC 27001imagesLoaded.

What is VBP's email format?

VBP's email format typically follows the pattern of First.Last@virtualbusinesspartners.com.au. Find more VBP email formats with LeadIQ.

When was VBP founded?

VBP was founded in 2013.

VBP

Q: What is VBP's official website and social media links?

VBP's official website is vbp.au. VBP has social profiles on LinkedIn.

Q: How many employees does VBP have currently?

VBP has approximately 1.1K employees.

Q: What technology does VBP use?

VBP's tech stack includes HTML, CSS, Envoy, Lucidchart, Facebook.

Financial ServicesNew South Wales, Australia1001-5000 Employees

Built for Advice Firms. Backed by Australian Leaders.

VBP isn’t just familiar with advice firms - we were built for them. Designed specifically for planners, accountants and brokers, we bring together a global delivery team with the backing of Australia’s most experienced financial services executives. The result: deep industry insight and execution you can trust.

As a certified B Corp and founding member of the EOAP, we meet the world’s highest standards for ethics, transparency and impact: so you can partner with a business that balances purpose with performance.

And when it comes to protecting your business, security isn’t optional. We’re ISO 27001 certified, the global gold standard for information security. Our systems and processes safeguard your data, comply with Australian privacy laws and give you complete peace of mind. Because with VBP, security comes standard.